

FIG. 1A

Title: TRANSGENIC MOUSE FOR TARGETED
RECOMBINATION MEDIATED BY MODIFIED
CRE-ER

Inventor(s): Pierre Chambon et al.

Appl. No.: 09/853,033

2 / 21




FIG. 1B




FIG. 1C




FIG. 1D

Title: TRANSGENIC MOUSE FOR TARGETED
RECOMBINATION MEDIATED BY MODIFIED
CRE-ER

Inventor(s): Pierre Chambon et al.

Appl. No.: 09/853,033



3 / 21




Fig. 2A

Title: TRANSGENIC MOUSE FOR TARGETED
RECOMBINATION MEDIATED BY MODIFIED
CRE-ER

Inventor(s): Pierre Chambon et al.

Appl. No.: 09/853,033



4 / 21




Fig. 2B






Fig. 3

6 / 21






Fig. 5




Fig.6A




Fig.6B




Fig. 6C




FIG. 6D




FIG. 6E




FIG. 6F

Title: TRANSGENIC MOUSE FOR TARGETED
RECOMBINATION MEDIATED BY MODIFIED
CRE-ER

Inventor(s): Pierre Chambon et al.

Appl. No.: 09/853,033

10 / 21




FIG. 7

Title: TRANSGENIC MOUSE FOR TARGETED
RECOMBINATION MEDIATED BY MODIFIED
CRE-ER

Inventor(s): Pierre Chambon et al.

Appl. No.: 09/853,033

11 / 21




Fig. 8




Fig. 9

Title: TRANSGENIC MOUSE FOR TARGETED
RECOMBINATION MEDIATED BY MODIFIED
CRE-ER

Inventor(s): Pierre Chambon et al.

Appl. No.: 09/853,033

13 / 21




FIG. 10

Title: TRANSGENIC MOUSE FOR TARGETED
RECOMBINATION MEDIATED BY MODIFIED
CRE-ER

Inventor(s): Pierre Chambon et al.

Appl. No.: 09/853,033



14 / 21




Fig. 11

Title: TRANSGENIC MOUSE FOR TARGETED
RECOMBINATION MEDIATED BY MODIFIED
CRE-ER

Inventor(s): Pierre Chambon et al.

Appl. No.: 09/853,033



15 / 21




FIG. 12A-B




FIG. 12C-D




FIG. 13A-B

Title: TRANSGENIC MOUSE FOR TARGETED
RECOMBINATION MEDIATED BY MODIFIED
CRE-ER

Inventor(s): Pierre Chambon et al.
Appl. No.: 09/853,033



18 / 21

Histological analysis of paraffin sections (5 μ m-thick) of biopsies of 8-16 mm tumors from CT and RXR α ep ^{-/-} mice, 25 and 30 weeks after the start of the DMBA/TPA treatment										
Weeks of DMBA/TPA treatment		number of tumors analysed	benign papillomas	Papillomas exhibiting						
				In situ carcinoma	FC	SCC (I)	SCC (II)	SCC(III)	SCC (IV)	SpCC
CT mice	25	20	19 (95 %)	1 (5%)	0	0	0	0	0	0
	30	31	25 (80 %)	1 (~3%)	5 (~16%)	0	0	0	0	0
RXR α ep ^{-/-} mice	25	20	10 (50 %)	2 (10%)	8 (40%)	0	0	0	0	0
	30	35	13 (37 %)	1 (~3%)	7 (20%)	3 (~9%)	3 (~9%)	1 (~3%)	2 (~6%)	2 (~6%)
										3 (~9%)

FC, focal carcinoma; SCC, squamous cell carcinoma; SpCC, spindle cell carcinoma; BCC , basal cell carcinoma

FIG. 13C




FIG. 14A-B




FIG. 14C




FIG. 15